Biomarin Pharmaceutical (BMRN) Non-Current Assets (2009 - 2026)
Biomarin Pharmaceutical (BMRN) recorded quarterly Non-Current Assets of $4.0 billion in Q1 2026, up 9.49% on a QoQ basis from $3.6 billion in Q4 2025, and up 8.34% year-over-year from $3.7 billion in Q1 2025.
Biomarin Pharmaceutical (BMRN) Non-Current Assets (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical has disclosed Non-Current Assets across 18 years of filings, most recently posting $4.0 billion for Q1 2026.
- Quarterly Non-Current Assets rose 8.34% year-over-year to $4.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.0 billion (changed 0.0% YoY) and the FY2025 annual result came in at $3.6 billion, down 3.09% from the prior year.
- Non-Current Assets grew to $4.0 billion in Q1 2026, from $3.6 billion in the prior quarter.
- Over five years, Non-Current Assets peaked at $4.0 billion in Q1 2026 and troughed at $3.6 billion in Q3 2022.
- A 5-year average of $3.7 billion and a median of $3.7 billion in 2025 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2025 — Non-Current Assets slipped 5.36% — and 2026, when it gained 8.34%.
- Tracing BMRN's Non-Current Assets over 5 years: stood at $3.6 billion in 2022, then grew by 7.23% to $3.9 billion in 2023, then slipped by 3.32% to $3.8 billion in 2024, then fell by 3.09% to $3.6 billion in 2025, then increased by 9.49% to $4.0 billion in 2026.
- Business Quant data shows BMRN's Non-Current Assets at $4.0 billion in Q1 2026, $3.6 billion in Q4 2025, and $3.8 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Biomarin Pharmaceutical | 10.52 Bn | 8.29 Bn | 571.21 Mn | 3.99 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.99 Bn |
| Dec 31, 2025 | 3.64 Bn |
| Sep 30, 2025 | 3.76 Bn |
| Jun 30, 2025 | 3.65 Bn |
| Mar 31, 2025 | 3.68 Bn |
| Dec 31, 2024 | 3.76 Bn |
| Sep 30, 2024 | 3.79 Bn |
| Jun 30, 2024 | 3.81 Bn |
| Mar 31, 2024 | 3.89 Bn |
| Dec 31, 2023 | 3.89 Bn |
| Sep 30, 2023 | 3.80 Bn |
| Jun 30, 2023 | 3.61 Bn |
| Mar 31, 2023 | 3.59 Bn |
| Dec 31, 2022 | 3.62 Bn |
| Sep 30, 2022 | 3.58 Bn |
| Jun 30, 2022 | 3.63 Bn |
| Mar 31, 2022 | 3.67 Bn |
| Dec 31, 2021 | 3.73 Bn |
| Sep 30, 2021 | 3.67 Bn |
| Jun 30, 2021 | 3.54 Bn |